Trial intelligence / Profile preview

Avastin with alternating XELIRI and XELOX in metastatic colorectal cancer

NCT01531595Phase 2Active, not recruiting

Start
Feb 2012
Primary completion
Dec 2025
Modality
Monoclonal Antibodies
Countries
1
01

Overview

A Phase 2 trial of bevacizumab in colorectal cancer (metastatic) (mCRC). Started Feb 2012; status: active, not recruiting.

02

Drugs

bevacizumab
03

Conditions

colorectal cancer (metastatic) (mCRC)

Beyond the preview

Go deeper on NCT01531595.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01531595.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call